3 Key Takeaways
Plain English Summary- 01Core Finding
Performance status, neurocognitive, ophthalmologic, audiologic, and radiologic assessments were performed at greater than one year following CM diagnosis.
- 02Study Evidence
Tested in a early human trial (Phase I/II) + observational cohort study at the Phase I/II stage.
- 03Practical Meaning
Early-stage human studies — dosing, durability, and rare side effects still require Phase III confirmation.
What This Means for You
In immunocompetent patients with CM-PIIRS, adjunctive corticosteroid therapy was associated with sustained improvement in neurologic, visual, and radiologic outcomes with mixed improvement in hearing after a year of therapy, with mild residual deficits.
The Discovery
Post-infectious inflammatory response syndrome (PIIRS) is an increasingly recognized complication of cryptococcal meningoencephalitis (CM) in non-HIV infected hosts with significant morbidity and mortality. Data describing long-term outcomes following immunomodulatory therapy are limited. We conducted a prospective observational study of 15 immunocompetent adults with CM-PIIRS treated with a pulse corticosteroid taper (PCT) regimen. Performance status, neurocognitive, ophthalmologic, audiologic, and radiologic assessments were performed at greater than one year following CM diagnosis. After one year, performance status continued to improve from both baseline and the post-pulse periods. Neurocognitive testing revealed mild residual deficits, within the limits of normal, most prominently in information processing and psychomotor speed. Ocular abnormalities were frequent at baseline but showed substantial and sustained reductions following PCT, particularly in retinal nerve fiber layer thickness. Visual field deficits improved substantially and remained stable thereafter. Evidence for changes in hearing sensitivity at post 1-year follow-up was mixed with 44.5% of ears meeting criteria for improvement, 11% for worsening, and 44.5% being stable. Radiologic abnormalities improved in 79% of patients, although intermittent inflammatory flares occurred during PCT but responded to dose escalation. A prolonged corticosteroid taper may be helpful, and MRI imaging can be used to evaluate response to taper.
How It Works, Simply
This infectious disease research focuses on inflammation · Immune response. Researchers evaluated it using an early human trial (Phase I/II) + Observational cohort study at the Phase I/II stage of medical research.
3 Key Takeaways
Clinical Takeaways- 01Core Finding
Performance status, neurocognitive, ophthalmologic, audiologic, and radiologic assessments were performed at greater than one year following CM diagnosis.
- 02Study Evidence
Tested in a early human trial (Phase I/II) + observational cohort study at the Phase I/II stage.
- 03Practical Meaning
Early-stage human studies — dosing, durability, and rare side effects still require Phase III confirmation.
Key Numbers
Biological Mechanism & Study Design
Study Design & Cohort
Early human trial (Phase I/II) + Observational cohort study
Early human trial (Phase I/II) + Observational cohort study · Phase I/II
Biological Pathway & Modality
Inflammation · Immune response
Intervention: Long-term Outcomes in Previously Healthy non-HIV Individuals with Cryptococcal
Experimental Findings & Endpoints
Post-infectious inflammatory response syndrome (PIIRS) is an increasingly recognized complication of cryptococcal meningoencephalitis (CM) in non-HIV infected hosts with significant morbidity and mortality.
Data describing long-term outcomes following immunomodulatory therapy are limited. We conducted a prospective observational study of 15 immunocompetent adults with CM-PIIRS treated with a pulse corticosteroid taper (PCT) regimen.
Performance status, neurocognitive, ophthalmologic, audiologic, and radiologic assessments were performed at greater than one year following CM diagnosis. After one year, performance status continued to improve from both baseline and the post-pulse periods.
Neurocognitive testing revealed mild residual deficits, within the limits of normal, most prominently in information processing and psychomotor speed. Ocular abnormalities were frequent at baseline but showed substantial and sustained reductions following PCT, particularly in retinal nerve fiber layer thickness.
Visual field deficits improved substantially and remained stable thereafter. Evidence for changes in hearing sensitivity at post 1-year follow-up was mixed with 44.5% of ears meeting criteria for improvement, 11% for worsening, and 44.5% being stable.
Radiologic abnormalities improved in 79% of patients, although intermittent inflammatory flares occurred during PCT but responded to dose escalation. A prolonged corticosteroid taper may be helpful, and MRI imaging can be used to evaluate response to taper.
Clinical Translation & Practice Context
In immunocompetent patients with CM-PIIRS, adjunctive corticosteroid therapy was associated with sustained improvement in neurologic, visual, and radiologic outcomes with mixed improvement in hearing after a year of therapy, with mild residual deficits.
The Bottom Line · Clinical Pearl
“In immunocompetent patients with CM-PIIRS, adjunctive corticosteroid therapy was associated with sustained improvement in neurologic, visual, and radiologic outcomes with mixed improvement in hearing after a year of therapy, with mild residual deficits.”
Published in The Journal of Infectious Diseases · Current Stage: Phase I/II